In addition, our cohort did not reflect the impact of current standard treatments due to an access barrier to immunotherapy (IO monotherapy, IO combinations and IO plus chemotherapy combo) in the NSCLC population without oncogenic drivers, and to third-generation EGFR-TKIs as first-line therapy in the EGFR-mutant population. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.